Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?

Changes in systolic blood pressure (SBP) during an admission for acute heart failure (AHF), especially those leading to hypotension, have been suggested to increase the risk for adverse outcomes.

[1]  Priyesh A. Patel,et al.  Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality: Findings From ASCEND-HF , 2014, Circulation. Heart failure.

[2]  C. O'connor,et al.  Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). , 2005, American heart journal.

[3]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[4]  P. Ponikowski,et al.  Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure , 2017, The New England journal of medicine.

[5]  David E. Booth,et al.  Analysis of Incomplete Multivariate Data , 2000, Technometrics.

[6]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[7]  K. Aaronson,et al.  Risk of death associated with nesiritide in patients with acutely decompensated heart failure. , 2006, JAMA.

[8]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[9]  P. Ponikowski,et al.  Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. , 2015, European heart journal.

[10]  P. Ponikowski,et al.  Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre‐RELAX‐AHF , 2011, European journal of heart failure.

[11]  C. O'connor,et al.  Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS) , 2017, European journal of heart failure.

[12]  G. Cotter,et al.  Intravenous therapies in acute heart failure – lack of effect or lack of well powered studies? , 2014, European journal of heart failure.

[13]  P. Ponikowski,et al.  Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine , 2015, European journal of heart failure.

[14]  C. O'connor,et al.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. , 2007, JAMA.

[15]  L. Ruilope,et al.  Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. , 2016, European heart journal.

[16]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.